3/25
02:06 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Neutral
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/17
02:02 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/11
02:33 pm
cbay
Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain [Yahoo! Finance]
Low
Report
Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain [Yahoo! Finance]
3/11
08:30 am
cbay
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer [Yahoo! Finance]
Low
Report
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer [Yahoo! Finance]
3/11
05:26 am
cbay
Global Primary Biliary Cholangitis Therapeutics Market 2024-2034 - Hospital Pharmacies Lead Distribution, But Online Pharmacies to Experience Rapid Growth Amid Digital Healthcare Boom [Yahoo! Finance]
Low
Report
Global Primary Biliary Cholangitis Therapeutics Market 2024-2034 - Hospital Pharmacies Lead Distribution, But Online Pharmacies to Experience Rapid Growth Amid Digital Healthcare Boom [Yahoo! Finance]
3/9
02:08 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/4
08:09 am
cbay
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis [Yahoo! Finance]
Low
Report
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis [Yahoo! Finance]
3/4
08:00 am
cbay
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
Low
Report
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
3/1
02:04 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
2/29
06:30 pm
cbay
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, SCTL, EVRI
Low
Report
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, SCTL, EVRI
2/29
12:25 pm
cbay
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
Low
Report
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
2/29
09:10 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $32.50 price target on the stock.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $32.50 price target on the stock.
2/28
04:53 pm
cbay
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/28
04:45 pm
cbay
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Low
Report
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
2/24
10:10 am
cbay
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE
Low
Report
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE
2/22
02:03 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
2/21
05:55 pm
cbay
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis [Yahoo! Finance]
Low
Report
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis [Yahoo! Finance]
2/21
05:43 pm
cbay
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
Low
Report
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
2/20
04:05 pm
cbay
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/20
08:12 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "market perform" rating re-affirmed by analysts at SVB Leerink LLC. They now have a $32.50 price target on the stock.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "market perform" rating re-affirmed by analysts at SVB Leerink LLC. They now have a $32.50 price target on the stock.
2/16
01:58 pm
cbay
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
Low
Report
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
2/15
10:00 am
cbay
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates [Yahoo! Finance]
Low
Report
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates [Yahoo! Finance]
2/15
03:08 am
cbay
Director Janet Dorling Sells 6,000 Shares of CymaBay Therapeutics Inc (CBAY) [Yahoo! Finance]
Low
Report
Director Janet Dorling Sells 6,000 Shares of CymaBay Therapeutics Inc (CBAY) [Yahoo! Finance]
2/14
08:40 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "market perform" rating re-affirmed by analysts at Lifesci Capital.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "market perform" rating re-affirmed by analysts at Lifesci Capital.
2/14
08:03 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $32.50 price target on the stock, down previously from $33.00.
Medium
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $32.50 price target on the stock, down previously from $33.00.